PRDM10

Across TCGA pan-cancer cohorts, PRDM10 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PRDM10 data layer compared with 27 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher PRDM10 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PRDM10 expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

LSCC, HNSC, and LUAD are the cancer types where PRDM10 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Quartile	II,III,IV	1.000	0.455	.001	41	view →
HNSC	DFS	Median	All	1.000	0.911	.003	10	view →
LUAD	OS	Quartile	III,IV	0.787	0.165	.015	6	view →
CCRCC	OS	Quartile	III,IV	0.977	0.629	.010	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PRDM10–LSCC (DFS)

Open the LSCC breakdown →